Fair pricing, policy and other strategies can ensure the successful and equitable introduction of lenacapavir
Lenacapavir, a groundbreaking HIV-1 capsid inhibitor developed by Gilead Sciences, stands on the brink of revolutionizing HIV prevention. As a potential long-acting pre-exposure prophylaxis option, it could transform the fight against the epidemic. Yet uncertainty surrounds its future pricing and accessibility, raising urgent questions for the communities hardest hit by HIV.
Read the full story at Think Global Health.
Source : Think Global Health
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.